SRNE News and Press, Sorrento Therapeutics Inc. From 07/20/21

Sorrento Therapeutics ([[SRNE]] -1.2%) company Scilex Holding has completed enrollment in late-stage trial of SP-102 for the treatment of lumbosacral radicular pain ((sciatica)).The trial has randomized 400 patients at 40 sites across 25 states in the U.S. with the pr...

Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announced complete enrollment of its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium p...

Sorrento Therapeutics' (SRNE) partner Mabpharm Ltd has received New Drug Application ((NDA)) approval for its infliximab biobetter antibody in China. Sorrento holds exclusive commercial rights to this product outside of China and plans to file a Biologics License Application ((BLA)) for the i...

China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China. Sorrento holds commercialization rights outside of China and intends to meet with regulatory agencies to determine best path to registration for the US ...

Serial deal maker Sorrento Therapeutics, Inc. has amassed a significant pipeline of immuno-oncology, pain management, and Covid-19 assets. The plethora of programs combined with its communication almost exclusively through press release renders it challenging to determine the company&...

This is not a good week to be Sorrento Therapeutics (NASDAQ: SRNE) or one of its investors. Despite an encouraging pop on Thursday, the company's shares were still down by slightly over 9% from the start of the week. Counterintuitively, the big lurch downwards came just after a blas...

Shares of biopharma stock Sorrento Therapeutics (NASDAQ: SRNE) rallied 28.9% in June, according to numbers provided by S&P Global Market Intelligence . Although the stock was already primed for bullishness following a steep pullback earlier in the year, a pair of drug trial ...

yodiyim/iStock via Getty Images The FDA has given the go-ahead to Sorrento Therapeutics ([[SRNE]] -2.0%) to start a Phase 2 clinical study of RTX in the treatment of moderate-to-severe osteoarthritis of the knee pain ((OAK)), the company announced today. The multi-center, double-bli...

Phase 2 trial of RTX for OA pain to proceed following FDA clearance. Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses tested up to 30 ug. Phase 1b data demonstrated significant efficacy supporting R...

The Biotech industry has been instrumental in developing treatments for the coronavirus. The sector’s long-term potential remains solid due to the aging populating and the rising cost of healthcare. Wall Street analysts expect biotech stocks Sorrento Therapeutics (SRNE) and Catabasis P...